AtaiBeckley (ATAI) Debt to Equity (2021 - 2026)

AtaiBeckley (ATAI) recorded quarterly Debt to Equity of $0.0 in Q1 2026, up 27.82% quarter-over-quarter from $0.0 in Q4 2025.

AtaiBeckley (ATAI) Debt to Equity (2021 - 2026) Analysis & Trends

AtaiBeckley's Debt to Equity history runs 3 years deep, the most recent figure standing at $0.0 for Q1 2026.

  • In Q1 2026, Debt to Equity changed N/A year-over-year to $0.0; the TTM figure through Mar 2026 stood at $0.0 (changed N/A YoY), while the FY2025 annual figure was $0.0, down 97.77% from the prior year.
  • Debt to Equity was $0.0 for Q1 2026 at AtaiBeckley, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.07 in Q1 2025 to a low of $0.0 in Q2 2021.
  • The 4-year median for Debt to Equity is $0.0 (2022), against an average of $0.01.
  • Biggest YoY gain for Debt to Equity was 97.77% in 2025; the steepest drop was 97.77% in 2025.
  • A 3-year view of Debt to Equity shows it stood at $0.05 in 2024, then tumbled by 97.77% to $0.0 in 2025, then climbed by 27.82% to $0.0 in 2026.
  • The last three Debt to Equity figures came in at $0.0 (Q1 2026), $0.0 (Q4 2025), and $0.05 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.32
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 AtaiBeckley 1.45 Bn 1.45 Bn - 0.00

Historic Data

Download Data
DateValue
Mar 31, 2026 0.00
Dec 31, 2025 0.00
Mar 31, 2025 0.07
Dec 31, 2024 0.00
Dec 31, 2024 0.05
Mar 31, 2024 0.00
Dec 31, 2022 0.00
Dec 31, 2021 0.00
Sep 30, 2021 0.00
Jun 30, 2021 0.00